2008 July 23 « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
July 2008

M T W T F S S

« Jun Aug »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

Ambrilia initiate Phase I/II trial of 3-month goserelin in Prostate cancer

Posted on July 23, 2008 by crimsoncanary

Ambrilia Biopharma have initiated a Phase I/II clinical trial its 3-month formulation of goserelin, in hormone-sensitive prostate cancer patients.

Filed under: Uncategorized | Tagged: Ambrilia, goserelin | Leave a Comment »